<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Steroid-resistant nephrotic syndrome in children: Etiology
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Steroid-resistant nephrotic syndrome in children: Etiology
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Steroid-resistant nephrotic syndrome in children: Etiology
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Olivia Gillion Boyer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H174704350">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of children who present with idiopathic nephrotic syndrome (NS) have minimal change disease, which is generally responsive to steroid therapy. As a result, empirical steroid therapy is given to most children who present with idiopathic NS.
        </p>
        <p>
         Steroid-resistant NS (SRNS) describes the cases that do not respond to initial steroid therapy. Approximately one-third of these cases are due to single gene variants that affect glomerular podocyte structure and/or function. These monogenic forms of SRNS are poorly responsive to immunosuppressive therapy and disease progression is rapid. Thus, therapeutic decisions in children with SRNS depend in part on the underlying etiology.
        </p>
        <p>
         The causes of SRNS in children will be reviewed here. The clinical manifestations, diagnosis, and initial management of NS, as well as the etiology of NS in children, are also discussed separately. In addition, the management of children with steroid-sensitive NS (SSNS) and those with SRNS are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children", section on 'Initial therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children", section on 'Steroid-sensitive nephrotic syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H174704558">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most children with SRNS, the underlying cause is not known [
         <a href="#rid1">
          1,2
         </a>
         ]. However, advances in molecular genetics of glomerular diseases have shown single gene defects that affect glomerular podocyte differentiation, structure, and function are responsible for one-third or more of all pediatric cases of SRNS  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3-10
         </a>
         ]. Confirmation of a genetic cause of SRNS is clinically important because patients with a genetic etiology respond poorly to immunosuppressive therapy and there is a lower risk of recurrence of primary disease after renal transplantation compared with those without a genetic etiology. (See
         <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H631397715">
         <span class="h1">
          GENETIC VARIANTS
         </span>
        </p>
        <p class="headingAnchor" id="H3881575837">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monogenic variants in over 60 genes have been identified as the etiology of SRNS in approximately 30 percent of children who present with SRNS  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ). This rate is likely to increase as more genes are identified in which variants result in SRNS. The likelihood of identifying a monogenic cause of SRNS increases with decreasing age and increases to 50 percent in children who are from a consanguineous family [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Variants of the following genes are the most common causes of hereditary isolated SRNS  (
         <a class="graphic graphic_table graphicRef107089" href="/z/d/graphic/107089.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid6">
          6,9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         encodes nephrin, a slit diaphragm component of the podocyte
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         encodes podocin, a slit diaphragm component of the podocyte
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         encodes phospholipase C epsilon
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=16711" target="_blank">
          <i>
           WT1
          </i>
         </a>
         encodes a transcription tumor suppressor protein, which is involved in kidney and gonad development
        </p>
        <p>
        </p>
        <p>
         SRNS is less commonly due to variants in the following genes [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610982&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4RYrdTxgIawL1YhehdtBfE&amp;TOPIC_ID=16711" target="_blank">
          <i>
           INF2
          </i>
         </a>
         (encodes an actin-regulating protein). (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'INF2 gene'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=16711" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         (encodes lamin beta 2, a basement membrane protein); a variant of this gene results in Pierson syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609049&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHaVDYEgGncusNCJ7EYrP37&amp;TOPIC_ID=16711" target="_blank">
          MIM #609049
         </a>
         ; also referred to as microcoria-congenital nephrosis syndrome), a rare autosomal recessive syndrome with characteristic findings of congenital NS, ocular malformations (microcoria, abnormal lens with cataracts, and retinal abnormalities), and neurologic symptoms (hypotonia, psychomotor retardation). (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Pierson syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606622&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrWbatR8%2Beg7BBIX6oz42%2FW&amp;TOPIC_ID=16711" target="_blank">
          <i>
           SMARCAL1
          </i>
         </a>
         (encodes a chromatin remodeling protein); a variant results in Schimke immunoosseous dysplasia (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F242900&amp;token=tEpDslnpc0F0kICl%2Fz7sFZDxK7ki9TNJyVXNO7kDVoMPBTU2aEjYedi2a%2FKXhz1i&amp;TOPIC_ID=16711" target="_blank">
          MIM #242900
         </a>
         ), an autosomal recessive condition with skeletal, kidney, and immune abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">
          "Syndromic immunodeficiencies", section on 'Schimke immunoosseous dysplasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603652&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp9DWWUOp9JcrQTkj2dLVo5&amp;TOPIC_ID=16711" target="_blank">
          <i>
           TRPC6
          </i>
         </a>
         (encodes the transient receptor potential 6 ion channel). (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'TRPC6 gene'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The frequency of specific genetic variants based on age was illustrated in a multicenter study of individuals from 1783 unrelated families with SRNS who presented before 25 years of age [
         <a href="#rid9">
          9
         </a>
         ]. In this cohort, a monogenic cause was identified in 30 percent of families, including 50 percent of consanguineous families and 25 percent of nonconsanguineous families.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The likelihood of a monogenetic cause of SRNS decreased with increasing age, as noted by the following relative frequencies of a monogenic diagnosis in families based on age:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         0 to 3 months – 69 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         4 to 12 months – 50 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         13 months to 6 years – 25 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         7 to 12 years – 18 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         13 to 17 years – 11 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &gt;18 years – 21 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of specific underlying genetic variants also varied with age:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who presented in the first three months of age, the most common causative variants occurred in
         <em>
          NPHS1
         </em>
         ,
         <em>
          NPHS2
         </em>
         ,
         <em>
          WT1
         </em>
         , and
         <em>
          LAMB2
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          NPHS2
         </em>
         variants were most frequently identified in patients who presented after one year of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          WT1
         </em>
         variants showed a biphasic distribution, with a first peak at 4 to 12 months and a second peak beyond 18 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 1 percent of cases, variants were identified in genes involved in the coenzyme Q10 biosynthesis pathway (
         <em>
          COQ2
         </em>
         ,
         <em>
          COQ6
         </em>
         ,
         <em>
          PDSS2
         </em>
         , and
         <em>
          ADCK4
         </em>
         ). This is an important etiology as it is the only one with an existing potential specific treatment (ie,
         <em>
          COQ10
         </em>
         supplementation) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other monoallelic pathogenic gene variants (
         <em>
          INF2
         </em>
         and
         <em>
          TRPC6
         </em>
         ) were most frequently detected in early adulthood.
        </p>
        <p>
        </p>
        <p>
         In another study from the SRNS Study Group, whole-exome sequencing identified genetic variants in 74 of 300 families (25 percent) [
         <a href="#rid12">
          12
         </a>
         ]. A variant was found in 38 percent of consanguineous families and in 13 percent of non-consanguineous families. Variants were detected in 20 of 33 SRNS genes.
         <em>
          NPHS1
         </em>
         ,
         <em>
          PLCE1
         </em>
         ,
         <em>
          NPHS2
         </em>
         , and
         <em>
          SMARCAL1
         </em>
         were the most common genes in which a variant was detected.
        </p>
        <p>
         It also appears that variants in a second gene may also occur in patients with SRNS [
         <a href="#rid13">
          13
         </a>
         ]. Although they might have modifier effects, the pathogenic potential of these additional sequence variants remains unclear.
        </p>
        <p class="headingAnchor" id="H3204732732">
         <span class="h2">
          Genotype and histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic findings that are consistent with specific gene variants can help guide genetic testing. However, most genetic causes of SRNS have histologic features that are not distinguishable from nongenetic disease, primarily focal segmental glomerulosclerosis (FSGS) [
         <a href="#rid5">
          5
         </a>
         ]. As a result, a kidney biopsy will generally not distinguish between genetic and nongenetic forms of SRNS.
        </p>
        <p>
         The following histologic features can be suggestive of a specific underlying gene defect:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diffuse mesangial sclerosis
         </strong>
         –
         <em>
          WT1
         </em>
         ,
         <em>
          LAMB2
         </em>
         , or
         <em>
          PLCE1
         </em>
         variants  (
         <a class="graphic graphic_picture graphicRef77219" href="/z/d/graphic/77219.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef56256" href="/z/d/graphic/56256.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tubulointerstitial changes
         </strong>
         – These include irregular microcystic dilatation of proximal tubules and are typically seen in patients with
         <em>
          NPHS1
         </em>
         variants  (
         <a class="graphic graphic_picture graphicRef57870" href="/z/d/graphic/57870.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef69624" href="/z/d/graphic/69624.html" rel="external">
          picture 4
         </a>
         ). However, dilation of the proximal tubules may be observed in other cases of congenital NS secondary to heavy proteinuria. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome of Finnish type'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2105154611">
         <span class="h2">
          Syndromic steroid-resistant nephrotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syndromic forms of genetic SRNS are due to the following gene variants. Nonrenal manifestations are helpful in determining the appropriate gene to test  (
         <a class="graphic graphic_table graphicRef107090" href="/z/d/graphic/107090.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Management", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=16711" target="_blank">
          <i>
           WT1
          </i>
         </a>
         are associated with several forms of hereditary NS, including Denys-Drash syndrome and Frasier syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis with Denys-Drash syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118045.html" rel="external">
          "Causes of differences of sex development", section on 'Global defects in testicular function'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F194080%3Fsearch%3DDenys-Drash+syndrome+%26highlight%3Dsyndromic+deny+drash+syndrome+denysdrash&amp;token=tEpDslnpc0F0kICl%2Fz7sFQdsXnRDd5WxpnJNX2h2G8MnXNJ2N7QQWzw8mbPgfOVSeo%2FitXi34JmFaavoPmnXtrZRJ7KqMKI9mtpZ%2FT5XlKSzvSBiHRCnouC50LEituLorwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=16711" target="_blank">
          Denys-Drash syndrome
         </a>
         (MIM #194080) consists of the triad of progressive kidney disease with diffuse mesangial sclerosis, male pseudohermaphroditism, and Wilms tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F136680%3Fsearch%3Dfrasier+syndrome%26highlight%3Dsyndromic+syndrome+frasier&amp;token=tEpDslnpc0F0kICl%2Fz7sFc6jRLzqNN8gxZwGEOirhGnzOEEh1%2Bk%2B3PoBVsNzAOos1MwkpcrZqgAYRhcxfJKKp1S1MJoE9KTny80gnkEzlvh4b387oB%2BtdF6xIeX0KPRP&amp;TOPIC_ID=16711" target="_blank">
          Frasier syndrome
         </a>
         (MIM #136680), characterized by male pseudohermaphroditism with female external genitalia and NS with FSGS, is considered a disease spectrum/continuum [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=16711" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         cause
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609049&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHaVDYEgGncusNCJ7EYrP37&amp;TOPIC_ID=16711" target="_blank">
          Pierson syndrome
         </a>
         (MIM #609049; diffuse mesangial sclerosis and ocular malformations). (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Pierson syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606622&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrWbatR8%2Beg7BBIX6oz42%2FW&amp;TOPIC_ID=16711" target="_blank">
          <i>
           SMARCAL1
          </i>
         </a>
         are associated with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F242900%3Fsearch%3DSchimke+immunoosseous+dysplasia%26highlight%3Dimmunoosseous+dysplasia+dysplastic+schimke&amp;token=tEpDslnpc0F0kICl%2Fz7sFZDxK7ki9TNJyVXNO7kDVoMqt%2Fag0MAvLb898UDZEZ3Tjq8QCH5HscEU190gtHxeHdy0GeuGLyF%2FSme8rsn9TIyftEOdPE3V3V6fo1ya5BXqHMBbxl447rbvoDdQSqzzHg%3D%3D&amp;TOPIC_ID=16711" target="_blank">
          Schimke syndrome
         </a>
         (MIM #242900), characterized by growth retardation, T cell deficiency, bone dysplasia, and cerebrovascular disease. Patients may develop SRNS with FSGS progressing to kidney failure [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">
          "Syndromic immunodeficiencies", section on 'Schimke immunoosseous dysplasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602575&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqRycEx7BxoRhqcU3%2Fm%2FaqN&amp;TOPIC_ID=16711" target="_blank">
          <i>
           LMX1B
          </i>
         </a>
         are associated with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F161200%3Fsearch%3Dnail+patella%26highlight%3Dnail+kneecap+kneepan+patella+patellar&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313WF5IZjJR52iIyMRr6iQlzZcRNP5w9ShAz3BI8u2ok4jcaqpUDW9zNIk22hA5yyJK8Js0nGseiaQyP8HMRvf8ZK&amp;TOPIC_ID=16711" target="_blank">
          nail-patella syndrome
         </a>
         (MIM#161200). Approximately one-half of patients develop proteinuria, sometimes with NS. (See
         <a class="medical medical_review" href="/z/d/html/6116.html" rel="external">
          "Nail-patella syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610982&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4RYrdTxgIawL1YhehdtBfE&amp;TOPIC_ID=16711" target="_blank">
          <i>
           INF2
          </i>
         </a>
         have been identified in patients with Charcot-Marie-Tooth neuropathy, including deafness associated with FSGS [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Galloway-Mowat syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F251300&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fl9cIUMPD4r9ezSmhgmbW2I&amp;TOPIC_ID=16711" target="_blank">
          MIM #251300
         </a>
         and others) is characterized by NS, microcephaly, and neurologic impairment [
         <a href="#rid21">
          21-24
         </a>
         ]. Disease-causing variants have been identified in 10 genes: OSGEP, TP53RK
         <em>
          ,
         </em>
         TPRKB,
         <em>
         </em>
         LAGE3, and
         <em>
          GON7
         </em>
         encoding the five subunits of the
         <em>
          KEOPS
         </em>
         complex; YRDC
         <em>
          involved in the same pathway
         </em>
         along with
         <em>
          WDR4
         </em>
         ,
         <em>
          WDR73
         </em>
         , and
         <em>
          NUP107
         </em>
         ; and
         <em>
          NUP133
         </em>
         [
         <a href="#rid21">
          21,24-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602257&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyomGKwRHgH2uEs8x0GZP0sT&amp;TOPIC_ID=16711" target="_blank">
          <i>
           SCARB2
          </i>
         </a>
         (
         <em>
          LIMP2
         </em>
         ), which encodes a lysosomal-membrane protein, are responsible for the action myoclonus-renal failure syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F254900&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fmgas2cQeQIN2Xh3GqBh%2FmP&amp;TOPIC_ID=16711" target="_blank">
          MIM #254900
         </a>
         ), an autosomal recessive disorder with FSGS, and progressive myoclonus epilepsy associated with storage material in the brain [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603729&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyovrjNGyO5U9tLiT3558D1u&amp;TOPIC_ID=16711" target="_blank">
          <i>
           SGPL1
          </i>
         </a>
         , encoding the ubiquitous sphingosine-1-phosphate enzyme, are responsible for SRNS and facultative ichthyosis, adrenal insufficiency, immunodeficiency, and neurologic defects [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2434938264">
         <span class="h2">
          Specific gene variants
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           NPHS1
          </em>
         </strong>
         –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         encodes nephrin, an integral membrane protein of the slit diaphragm of the podocyte. Biallelic pathogenic variants in
         <em>
          NPHS1
         </em>
         are most often associated with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F256300%3Fsearch%3DNPHS1%26highlight%3Dnphs1&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fk0vejr9JIKqxVnIZrnrKr6cgk3R40JCQEfjWjfOTbYKjIFmyEA%2BbH2iw6sVujkECw%3D&amp;TOPIC_ID=16711" target="_blank">
          Finnish-type congenital NS
         </a>
         (MIM #256300), which is generally diagnosed before three months of age. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome of Finnish type'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, variants of this gene have also been reported in older patients with SRNS, as illustrated in a study of 160 children with SRNS from 142 families that identified
         <em>
          NPHS1
         </em>
         variants in two related and nine unrelated patients (age range between 6 months and 11 years) [
         <a href="#rid30">
          30
         </a>
         ]. Another study reported compound heterozygous or homozygous
         <em>
          NPHS1
         </em>
         variants in five familial and seven sporadic cases of SRNS, including three with childhood-onset and one with adult-onset FSGS (patient 27 years old at onset) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           NPHS2
          </em>
         </strong>
         –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         encodes podocin, an integral membrane protein found exclusively in glomerular podocytes. Biallelic pathogenic variants in NPHS2 are frequently observed in children with familial SRNS, less commonly in those with sporadic SRNS, and are not found in patients with steroid-sensitive NS (SSNS) [
         <a href="#rid32">
          32-34
         </a>
         ]. The incidence of
         <em>
          NPHS2
         </em>
         variants varies among populations.
         <em>
          NPHS2
         </em>
         variants occur in approximately 10 to 30 percent of cases of sporadic SRNS in children from Europe and the Middle East [
         <a href="#rid33">
          33,35-39
         </a>
         ] and approximately 30 to 40 percent of familial cases [
         <a href="#rid33">
          33,39,40
         </a>
         ]. In contrast, the frequency of
         <em>
          NPHS2
         </em>
         pathogenic variants is low in Black Americans with SRNS [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More than 110 variants in the
         <em>
          NPHS2
         </em>
         have been reported [
         <a href="#rid40">
          40
         </a>
         ]. Most affected children appear to have an early onset of disease and progress to kidney failure [
         <a href="#rid35">
          35,37,42
         </a>
         ]. Cardiac defects have also been described in these patients [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, some affected patients have milder disease and present in adolescence or young adulthood. These patients have common p.R229Q variants inherited in combination with trans-associated variant in the N-terminal region of the gene [
         <a href="#rid44">
          44
         </a>
         ]. This does not follow Mendelian laws. In addition, some affected patients may respond to intensified immunosuppression and others may have recurrent nephrosis following kidney transplantation. This association of the p.R229Q variant and an N-terminal variant may account for the rare cases of recurrent primary disease in the transplant for patients with
         <em>
          NPHS2
         </em>
         gene variants. (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'NPHS2 gene'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">
          "Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney", section on 'Epidemiology and risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           PLCE1
          </em>
         </strong>
         – Biallelic pathogenic variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         cause NS type 3 (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610725&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7kscXiu13gi20PwR3Z8MfA&amp;TOPIC_ID=16711" target="_blank">
          MIM #610725
         </a>
         ) and are usually associated with congenital NS and diffuse mesangial sclerosis but may also occur in older patients. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a cohort of 139 patients (mean age 23 months, range 0 to 31 years) with early-onset SRNS and diffuse mesangial sclerosis,
         <em>
          PLCE1
         </em>
         variants were found in 8 percent (6 of 78) of FSGS cases without
         <em>
          NPHS2
         </em>
         variants [
         <a href="#rid45">
          45
         </a>
         ]. Incomplete penetrance was demonstrated with three unaffected and unrelated individuals found to carry the homozygous pathogenic variants identified in their respective families, a very rare finding in autosomal recessive disorders [
         <a href="#rid45">
          45
         </a>
         ]. It is speculated that modifier genes or environmental factors, yet to be identified, may play a role in the kidney phenotype variability observed. This observation needs to be considered when genetic counselling is offered to families. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           WT1
          </em>
         </strong>
         – Monoallelic pathogenic variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=16711" target="_blank">
          <i>
           WT1
          </i>
         </a>
         , the Wilms tumor suppressor gene, have been reported in patients who present clinically with sporadic SRNS. In a European study of 115 cases of sporadic SRNS and 110 cases of SSNS,
         <em>
          WT1
         </em>
         variants were found in 3 of 60 males (5 percent) and 5 of 55 females (9 percent) with steroid-resistant disease and no variant was found in cases of SSNS [
         <a href="#rid15">
          15
         </a>
         ]. In addition, WT1 variants have been identified in families with autosomal dominant FSGS [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with
         <em>
          WT1
         </em>
         variants and SRNS are at risk for other extrarenal manifestations, including genitourinary abnormalities, Wilms tumor, and, less frequently, gonadoblastoma [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'WAGR syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mitochondrial cytopathies
         </strong>
         – Variants in the nuclear or mitochondrial genome that cause mitochondrial cytopathies include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The mitochondrial 3243A&gt;G variant in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F590050&amp;token=tEpDslnpc0F0kICl%2Fz7sFdjD%2BQo2qciDf1%2FZrD6VV4tTnUkiTKB%2F8AvUkZ3B0zNO&amp;TOPIC_ID=16711" target="_blank">
          <i>
           MTTL1
          </i>
         </a>
         gene is responsible for the MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, stroke-like episodes,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F540000&amp;token=tEpDslnpc0F0kICl%2Fz7sFTlMHs0hLkTLvZ2jBgsrFitNLNMZfdIW0bsiY1DXmIsd&amp;TOPIC_ID=16711" target="_blank">
          MIM #540000
         </a>
         ), which may also cause nephrotic-range proteinuria with FSGS that progresses to chronic kidney disease in 50 percent of cases [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variants in the mitochondrial gene complex
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F516060&amp;token=tEpDslnpc0F0kICl%2Fz7sFXmdQzxlDICA1%2FYT5WsX1dZff9rZxo8VqqJf51XjvzYM&amp;TOPIC_ID=16711" target="_blank">
          <i>
           MTATP6
          </i>
         </a>
         were associated with nephrotic-range proteinuria with FSGS in an individual with NARP syndrome (neuropathy, ataxia, retinitis pigmentosa,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F551500&amp;token=tEpDslnpc0F0kICl%2Fz7sFVUH92jsKZBqveSwA4bma1Jir%2BYQ4cfFHWv6BUftez8h&amp;TOPIC_ID=16711" target="_blank">
          MIM #551500
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biallelic pathogenic variants of several genes encoding proteins involved in the biosynthesis of CoQ10 (ubiquinone) may be responsible for steroid-resistant FSGS, including
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609825&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHp%2B5KsecK5vQopUgERZe76&amp;TOPIC_ID=16711" target="_blank">
          <i>
           COQ2
          </i>
         </a>
         [
         <a href="#rid50">
          50
         </a>
         ],
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614647&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4ktyw1uLF7dy9lVKR2v5e2&amp;TOPIC_ID=16711" target="_blank">
          <i>
           COQ6
          </i>
         </a>
         [
         <a href="#rid51">
          51-53
         </a>
         ],
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610564&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5o4N5IKrrMIN5A17%2B0T50K&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PDSS2
          </i>
         </a>
         [
         <a href="#rid54">
          54
         </a>
         ], and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615567&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7GRekhr9aoosDLB4C%2BxaR7&amp;TOPIC_ID=16711" target="_blank">
          <i>
           COQ8B
          </i>
         </a>
         (
         <em>
          ADCK4
         </em>
         ) [
         <a href="#rid55">
          55-57
         </a>
         ]. Case reports suggest that CoQ10 administration may reduce proteinuria and potentially be renoprotective [
         <a href="#rid9">
          9,58,59
         </a>
         ]. Of note, variants of these genes have presented with both steroid-resistant FSGS and sensorineural hearing loss [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other genes
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autosomal dominant
         </strong>
         (see
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604638&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrnEKRGGtSdn1VH34oog11c&amp;TOPIC_ID=16711" target="_blank">
          <i>
           ACTN4
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603652&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp9DWWUOp9JcrQTkj2dLVo5&amp;TOPIC_ID=16711" target="_blank">
          <i>
           TRPC6
          </i>
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ], and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610982&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4RYrdTxgIawL1YhehdtBfE&amp;TOPIC_ID=16711" target="_blank">
          <i>
           INF2
          </i>
         </a>
         have been associated with SRNS with FSGS that typically presents in adolescence and young adulthood [
         <a href="#rid61">
          61
         </a>
         ].
         <em>
          INF2
         </em>
         variants are a major cause of autosomal dominant SRNS/FSGS and are detected in 12 to 17 percent of affected families [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F167409&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313UVNEgM%2FwLc0veYqbV6PXWI&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PAX2
          </i>
         </a>
         have been reported in patients with FSGS, aged 7 to 68 years at onset of disease, and in the absence of extrarenal symptoms [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610586&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6HUxbK4nHxaeLGUw7JmFmw&amp;TOPIC_ID=16711" target="_blank">
          <i>
           ARHGAP24
          </i>
         </a>
         , which encodes an actin regulatory protein expressed in podocytes, were identified in a family with FSGS progressing to kidney failure [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616027&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6E2HWif0ygg3%2BajMgIILbH&amp;TOPIC_ID=16711" target="_blank">
          <i>
           ANLN
          </i>
         </a>
         , which encodes anillin, were identified in two families with autosomal dominant FSGS, with an age at onset of proteinuria ranging from 9 to 69 years [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autosomal recessive
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609720&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE7Q5C%2B%2FrvQw24oY2fr6zkB&amp;TOPIC_ID=16711" target="_blank">
          <i>
           CRB2
          </i>
         </a>
         were reported in four different families affected by SRNS [
         <a href="#rid67">
          67
         </a>
         ]. The protein product is implicated in podocyte apico-basal polarity.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F612014&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6lXzbEOb2m7%2BUTpcuEP2Zo&amp;TOPIC_ID=16711" target="_blank">
          <i>
           TTC21B
          </i>
         </a>
         cause nephronophthisis. In addition, the most common variant (p.P209L) was identified in seven families with FSGS, with onset ranging from 9 to 23 years [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in nuclear pore genes
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614351&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5eC5cRZ%2FH8fszSIcXxbhUy&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NUP93
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614352&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6m0Dgv1K8aFZIyw62a2Z%2Bo&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NUP205
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607617&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoUvAeYfJtq9xfWYOX4Otyu&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NUP107
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607845&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoTzY6oGUi%2FUPtJZ5JQcOUK&amp;TOPIC_ID=16711" target="_blank">
          <i>
           XPO5
          </i>
         </a>
         , which encode components of the nuclear pore complex [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602334&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoXk9FVpkieOpsoDINqwmS9&amp;TOPIC_ID=16711" target="_blank">
          <i>
           EMP2
          </i>
         </a>
         have been found in four individuals from three unrelated families. Three of these patients had SSNS, while one had SRNS with minimal changes on kidney biopsy [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600579&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoCHJ9rOt6hxFDPl75%2FukfO&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PTPRO
          </i>
         </a>
         (
         <em>
          GLEPP1
         </em>
         ) were identified in five children from two unrelated Turkish families. Four of the five patients were partially responsive to intensified immunosuppressive treatment. One patient progressed to kidney failure [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607704&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypWn82MAFAqSTJpbF%2FfahPp&amp;TOPIC_ID=16711" target="_blank">
          <i>
           KANK1
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614610&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6oX9kfgO81Xa6%2Fs1ZkTzeJ&amp;TOPIC_ID=16711" target="_blank">
          <i>
           KANK2
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614612&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6NTA%2BMKfTHoCvgt8jobyh2&amp;TOPIC_ID=16711" target="_blank">
          <i>
           KANK4
          </i>
         </a>
         have been detected in three children with SSNS and three children with SRNS and hematuria [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601479&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypjeUFj21exiIo1%2FKfPi0d1&amp;TOPIC_ID=16711" target="_blank">
          <i>
           MYO1E
          </i>
         </a>
         have been identified in children with SRNS and FSGS in two families [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Genetic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603743&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypSZGY9zp45pqEU9EoggwhI&amp;TOPIC_ID=16711" target="_blank">
          <i>
           APOL1
          </i>
         </a>
         , which encodes apolipoprotein L1, have been found to be associated with FSGS in individuals of sub-Saharan African descent [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          X-linked
         </strong>
         – Two different X-linked
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F301027&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6FJsghE0%2BFApyBeXPKWpd%2BZ&amp;TOPIC_ID=16711" target="_blank">
          <i>
           TBC1D8B
          </i>
         </a>
         hemizygous missense variants in two unrelated pedigrees were identified in boys affected with early-onset SRNS and FSGS, whereas the mothers and a sister bearing the same variant had no or milder symptoms [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H312325">
         <span class="h1">
          NONGENETIC IDENTIFIABLE CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As of 2015, no underlying genetic defects were identified in approximately 50 to 70 percent of pediatric patients with SRNS in Europe and the Middle East [
         <a href="#rid3">
          3,9
         </a>
         ]. The prevalence of nongenetic forms of SRNS in patients from North America, which is a more heterogenetic population, is unknown. In patients in whom an underlying cause is unknown, it is possible that pathogenic variants in yet-to-be-identified genes are responsible [
         <a href="#rid77">
          77
         </a>
         ]. For example, one report found that children with initial steroid resistance show decreased glucocorticoid receptor expression in peripheral blood mononuclear cells before starting therapy compared with steroid-sensitive children [
         <a href="#rid78">
          78
         </a>
         ]. This low expression, which may be genetically based, may be one of the pathophysiologic mechanisms of steroid resistance in children.
        </p>
        <p>
         In a case series of 91 children with SRNS from Germany, 41 patients did not have a pathogenic variant of any of the analyzed genes (
         <em>
          NPHS1
         </em>
         ,
         <em>
          NPHS2
         </em>
         ,
         <em>
          WTI
         </em>
         ,
         <em>
          LAMB2
         </em>
         ,
         <em>
          TRPC6
         </em>
         , and
         <em>
          PLCE1
         </em>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Kidney biopsies were performed in 40 of these 41 patients without an identifiable genetic cause and showed the following histologic diagnoses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal segmental glomerulosclerosis (FSGS; n = 28)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimal change disease (n = 10)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse mesangial sclerosis (n = 1)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mesangial proliferation (n = 1)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3128645537">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110405.html" rel="external">
          "Society guideline links: Nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H174704431">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ten to 20 percent of children with idiopathic nephrotic syndrome (NS) will fail to respond to initial empirical steroid therapy. These children with steroid-resistant NS (SRNS) are at increased risk for developing kidney failure. (See
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children", section on 'Outcome based on response'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monogenic pathogenic variants in over 60 genes have been identified as the etiology of SRNS in approximately 30 percent of children who present with SRNS  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ). This rate is likely to increase as more genes are identified, in which variants result in SRNS. The likelihood of identifying a monogenic cause of SRNS decreases with increasing age and increases to 50 percent in children who are from a consanguineous family. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variants of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=16711" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=16711" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=16711" target="_blank">
          <i>
           WT1
          </i>
         </a>
         genes are the most commonly identified genetic defects observed in pediatric SRNS. (See
         <a class="local">
          'Genetic variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several monogenic variants result in syndromic forms of SRNS  (
         <a class="graphic graphic_table graphicRef107090" href="/z/d/graphic/107090.html" rel="external">
          table 3
         </a>
         ). Nonrenal manifestations are helpful in determining the appropriate gene to test. (See
         <a class="local">
          'Syndromic steroid-resistant nephrotic syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite the growing number of identified causative variants, no underlying cause can be identified in most pediatric patients with SRNS. In these patients, the most common histologic diagnosis based on kidney biopsies is focal segmental glomerulosclerosis (FSGS), followed by minimal change disease. (See
         <a class="local">
          'Nongenetic identifiable causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1506939439">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William Smoyer, MD, FASN, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Haack D, Schärer K, Asam-Tauscher A, Vecsei P. Glucocorticoid receptors in idiopathic nephrotic syndrome. Pediatr Nephrol 1999; 13:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büscher AK, Kranz B, Büscher R, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2010; 5:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015; 10:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovric S, Ashraf S, Tan W, Hildebrandt F. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 2016; 31:1802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang F, Zhang Y, Mao J, et al. Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2017; 32:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015; 26:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bezdíčka M, Štolbová Š, Seeman T, et al. Genetic diagnosis of steroid-resistant nephrotic syndrome in a longitudinal collection of Czech and Slovak patients: a high proportion of causative variants in NUP93. Pediatr Nephrol 2018; 33:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan W, Airik R. Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome. Pediatr Nephrol 2021; 36:3515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warejko JK, Tan W, Daga A, et al. Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol 2018; 13:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber S, Büscher AK, Hagmann H, et al. Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing. Pediatr Nephrol 2016; 31:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol 2010; 25:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruf RG, Schultheiss M, Lichtenberger A, et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004; 66:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipska-Ziętkiewicz BS, Ozaltin F, Hölttä T, et al. Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group. Eur J Hum Genet 2020; 28:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Schaefer F, Haffner D, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nat Rev Nephrol 2021; 17:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clewing JM, Antalfy BC, Lücke T, et al. Schimke immuno-osseous dysplasia: a clinicopathological correlation. J Med Genet 2007; 44:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zivicnjak M, Franke D, Zenker M, et al. SMARCAL1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome. Pediatr Res 2009; 65:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Nevo F, Plaisier E, et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 2011; 365:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colin E, Huynh Cong E, Mollet G, et al. Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome. Am J Hum Genet 2014; 95:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vodopiutz J, Seidl R, Prayer D, et al. WDR73 Mutations Cause Infantile Neurodegeneration and Variable Glomerular Kidney Disease. Hum Mutat 2015; 36:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jinks RN, Puffenberger EG, Baple E, et al. Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73. Brain 2015; 138:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Rao J, Mollet G, et al. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nat Genet 2017; 49:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrondel C, Missoury S, Snoek R, et al. Defects in t6A tRNA modification due to GON7 and YRDC mutations lead to Galloway-Mowat syndrome. Nat Commun 2019; 10:3967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Shril S, Sinha A, et al. Mutations in WDR4 as a new cause of Galloway-Mowat syndrome. Am J Med Genet A 2018; 176:2460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosti RO, Sotak BN, Bielas SL, et al. Homozygous mutation in NUP107 leads to microcephaly with steroid-resistant nephrotic condition similar to Galloway-Mowat syndrome. J Med Genet 2017; 54:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkovic SF, Dibbens LM, Oshlack A, et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet 2008; 82:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest 2017; 127:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santín S, García-Maset R, Ruíz P, et al. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009; 76:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:2742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karle SM, Uetz B, Ronner V, et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishberg Y, Rinat C, Megged O, et al. Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children. J Am Soc Nephrol 2002; 13:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berdeli A, Mir S, Yavascan O, et al. NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome. Pediatr Nephrol 2007; 22:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum. Hum Mutat 2014; 35:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernin G, Heeringa SF, Gbadegesin R, et al. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchshuber A, Jean G, Gribouval O, et al. Mapping a gene (SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confirms a distinct entity of autosomal recessive nephrosis. Hum Mol Genet 1995; 4:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishberg Y, Feinstein S, Rinat C, et al. The heart of children with steroid-resistant nephrotic syndrome: is it all podocin? J Am Soc Nephrol 2006; 17:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tory K, Menyhárd DK, Woerner S, et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet 2014; 46:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Benoit G, Gribouval O, et al. Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. J Med Genet 2010; 47:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall G, Gbadegesin RA, Lavin P, et al. A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS. J Am Soc Nephrol 2015; 26:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipska BS, Ranchin B, Iatropoulos P, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney Int 2014; 85:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol 2012; 27:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemoine S, Panaye M, Rabeyrin M, et al. Renal Involvement in Neuropathy, Ataxia, Retinitis Pigmentosa (NARP) Syndrome: A Case Report. Am J Kidney Dis 2018; 71:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007; 18:2773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 2011; 121:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park E, Ahn YH, Kang HG, et al. COQ6 Mutations in Children With Steroid-Resistant Focal Segmental Glomerulosclerosis and Sensorineural Hearing Loss. Am J Kidney Dis 2017; 70:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stańczyk M, Bałasz-Chmielewska I, Lipska-Ziętkiewicz B, Tkaczyk M. CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report. Pediatr Nephrol 2018; 33:2383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, et al. ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS. J Am Soc Nephrol 2016; 27:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashraf S, Gee HY, Woerner S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013; 123:5179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park E, Kang HG, Choi YH, et al. Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations. Pediatr Nephrol 2017; 32:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358:2849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. Pediatr Nephrol 2017; 32:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barua M, Stellacci E, Stella L, et al. Mutations in PAX2 associate with adult-onset FSGS. J Am Soc Nephrol 2014; 25:1942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vivante A, Chacham OS, Shril S, et al. Dominant PAX2 mutations may cause steroid-resistant nephrotic syndrome and FSGS in children. Pediatr Nephrol 2019; 34:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akilesh S, Suleiman H, Yu H, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011; 121:4127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gbadegesin RA, Hall G, Adeyemo A, et al. Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol 2014; 25:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebarasi L, Ashraf S, Bierzynska A, et al. Defects of CRB2 cause steroid-resistant nephrotic syndrome. Am J Hum Genet 2015; 96:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huynh Cong E, Bizet AA, Boyer O, et al. A homozygous missense mutation in the ciliary gene TTC21B causes familial FSGS. J Am Soc Nephrol 2014; 25:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Sadowski CE, Kohl S, et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 2016; 48:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park E, Ahn YH, Kang HG, et al. NUP107 mutations in children with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2017; 32:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gee HY, Ashraf S, Wan X, et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet 2014; 94:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozaltin F, Ibsirlioglu T, Taskiran EZ, et al. Disruption of PTPRO causes childhood-onset nephrotic syndrome. Am J Hum Genet 2011; 89:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gee HY, Zhang F, Ashraf S, et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest 2015; 125:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mele C, Iatropoulos P, Donadelli R, et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011; 365:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2017; 12:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorval G, Kuzmuk V, Gribouval O, et al. TBC1D8B Loss-of-Function Mutations Lead to X-Linked Nephrotic Syndrome via Defective Trafficking Pathways. Am J Hum Genet 2019; 104:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol 2004; 19:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammad A, Yahia S, Gouida MS, et al. Low expression of glucocorticoid receptors in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2013; 28:759.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16711 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10502121" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Glucocorticoid receptors in idiopathic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16105061" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : High incidence of initial and late steroid resistance in childhood nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798252" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20382325" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genetic kidney diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21415313" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25635037" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26507970" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genetic testing in steroid-resistant nephrotic syndrome: when and how?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28204945" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25349199" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29869118" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Genetic diagnosis of steroid-resistant nephrotic syndrome in a longitudinal collection of Czech and Slovak patients: a high proportion of causative variants in NUP93.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33479824" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29127259" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26248470" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20333530" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253707" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32467597" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33514942" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16840568" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Schimke immuno-osseous dysplasia: a clinicopathological correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19127206" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : SMARCAL1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22187985" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25466283" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26123727" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : WDR73 Mutations Cause Infantile Neurodegeneration and Variable Glomerular Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26070982" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28805828" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31481669" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Defects in t6A tRNA modification due to GON7 and YRDC mutations lead to Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30079490" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mutations in WDR4 as a new cause of Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28280135" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Homozygous mutation in NUP107 leads to microcephaly with steroid-resistant nephrotic condition similar to Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308289" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28165339" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18614772" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19812541" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10742096" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253708" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14978175" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729243" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805166" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805168" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707396" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Broadening the spectrum of diseases related to podocin mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17899208" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24227627" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18543005" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589695" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mapping a gene (SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confirms a distinct entity of autosomal recessive nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291839" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The heart of children with steroid-resistant nephrotic syndrome: is it all podocin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24509478" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20591883" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25145932" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24402088" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Genotype-phenotype associations in WT1 glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21656172" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renal involvement in mitochondrial cytopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29224958" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Renal Involvement in Neuropathy, Ataxia, Retinitis Pigmentosa (NARP) Syndrome: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855635" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21540551" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28117207" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : COQ6 Mutations in Children With Steroid-Resistant Focal Segmental Glomerulosclerosis and Sensorineural Hearing Loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232548" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17186472" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25967120" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24270420" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28405841" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579827" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28337616" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15879175" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20023659" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21258034" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24676634" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Mutations in PAX2 associate with adult-onset FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31001663" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Dominant PAX2 mutations may cause steroid-resistant nephrotic syndrome and FSGS in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21911940" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24676636" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25557779" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Defects of CRB2 cause steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24876116" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A homozygous missense mutation in the ciliary gene TTC21B causes familial FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26878725" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27190346" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : NUP107 mutations in children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24814193" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Mutations in EMP2 cause childhood-onset nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21722858" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Disruption of PTPRO causes childhood-onset nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25961457" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : KANK deficiency leads to podocyte dysfunction and nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21756023" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : MYO1E mutations and childhood familial focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28242845" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Focal Segmental Glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30661770" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : TBC1D8B Loss-of-Function Mutations Lead to X-Linked Nephrotic Syndrome via Defective Trafficking Pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503167" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Genetic forms of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23299233" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Low expression of glucocorticoid receptors in children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
